vaistinė Irmeda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 278,516 | 307,537 | 375,859 | 378,153 | 323,699 | 341,610 | 400,280 | 499,197 |
| Profit before tax | 101,952 | 3,669 | 610 | 3,800 | 4,100 | 406 | 4,740 | 1,505 |
| Net profit | 102,678 | 3,119 | 610 | 3,230 | 3,485 | 346 | 5,451 | 1,731 |
| Equity | 53,885 | 63,119 | 66,577 | 69,807 | 43,967 | 44,307 | 48,336 | 0 |
| Liabilities | 37,536 | 49,711 | 49,441 | 41,819 | 37,440 | 45,546 | 79,331 | 0 |
| Non-current assets | 3,477 | 11,500 | 9,100 | 6,700 | 0 | 0 | 0 | 0 |
| Current assets | 87,944 | 101,330 | 106,918 | 104,926 | 81,407 | 89,853 | 127,667 | 101,995 |
| Total assets | 91,421 | 112,830 | 116,018 | 111,626 | 81,407 | 89,853 | 127,667 | 101,995 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 4,780 | 2,529 | 10,245 |
| Social insurance contributions | - | - | - | - | - | 7,500 | 8,173 | 9,087 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -11.7% | +10.4% | +22.2% | +0.6% | -14.4% | +5.5% | +17.2% | +24.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 112.3% | 2.8% | 0.5% | 2.9% | 4.3% | 0.4% | 4.3% | 1.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 190.6% | 4.9% | 0.9% | 4.6% | 7.9% | 0.8% | 11.3% | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 36.9% | 1.0% | 0.2% | 0.9% | 1.1% | 0.1% | 1.4% | 0.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 36.6% | 1.2% | 0.2% | 1.0% | 1.3% | 0.1% | 1.2% | 0.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.7 | 0.8 | 0.7 | 0.6 | 0.9 | 1.0 | 1.6 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 69,629 | 70,971 | 93,965 | 94,538 | 80,925 | 85,403 | 100,070 | 124,799 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
vaistinė Irmeda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-05-16 | 2023-05-17 | 0.11 |
| 2023-05-02 | 2023-05-04 | 0.11 |
| 2023-04-25 | 2023-04-28 | 0.11 |
| 2023-03-16 | 2023-03-19 | 73.50 |
| 2022-08-23 | 2022-08-24 | 1.00 |
| 2022-07-18 | 2022-08-07 | 1.00 |
| 2022-06-16 | 2022-07-10 | 1.00 |
| 2022-05-26 | 2022-06-07 | 1.00 |
| 2022-03-16 | 2022-03-17 | 551.52 |
| 2021-12-16 | 2021-12-19 | 0.01 |
| 2021-11-16 | 2021-12-12 | 0.01 |
| 2021-10-18 | 2021-11-14 | 0.01 |
| 2021-09-16 | 2021-10-10 | 0.01 |
vaistinė Irmeda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-03-08 | 2026-03-12 | 235.66 |
| 2025-03-11 | 2025-03-12 | 759.9 |
| 2025-03-10 | 2025-03-10 | 525.02 |
| 2025-03-02 | 2025-03-09 | 523.9 |
| 2025-02-28 | 2025-03-01 | 519.14 |
| 2025-02-20 | 2025-02-27 | 498.16 |
| 2025-02-02 | 2025-02-10 | 0.56 |
| 2025-01-31 | 2025-02-01 | 0.28 |
| 2025-01-30 | 2025-01-30 | 0.08 |
| 2024-11-28 | 2024-12-08 | 0.03 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Irmeda, UAB (code 163658094) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €499.2K, up 24.7% year on year and 46.1% over two years, while net profit was €1.7K. Profitability remained thin, with a profit margin of 0.3%, after €5.5K in net profit in 2024 and €346 in 2023. The three-year pattern shows steadily rising turnover from €341.6K in 2023 to €400.3K in 2024 and €499.2K in 2025, but weaker earnings in the latest year. Total assets stood at €102.0K in 2025, below €127.7K in 2024. In 2024, equity was €48.3K and liabilities €79.3K. Key efficiency indicators point to strong asset use, with asset turnover of 4.89x and ROA of 1.7% for 2025. Revenue per employee was €124.8K, while profit per employee was €433, indicating high sales volume but limited bottom-line conversion.